Trulicity and Ozempic are not the same drug. They are both once-weekly GLP-1 receptor agonist injections for type 2 diabetes, but Trulicity contains dulaglutide and Ozempic contains semaglutide. Ozempic is typically more potent for A1C reduction and weight loss; Trulicity is slightly simpler to use. They share class side effects and cardiovascular benefits.
Same Drug Class, Different Molecules
Both Trulicity (dulaglutide) and Ozempic (semaglutide) belong to the glucagon-like peptide-1 receptor agonist class. They mimic the natural gut hormone GLP-1, which:
- Stimulates glucose-dependent insulin release from the pancreas
- Suppresses glucagon when blood sugar is high
- Slows gastric emptying
- Acts on appetite centers in the brain to reduce hunger
The differences between the two come down to molecular structure, half-life, dosing format, potency, and pricing.
Side-by-Side Comparison
| Feature | Trulicity (Dulaglutide) | Ozempic (Semaglutide) |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA approval (T2D) | 2014 | 2017 |
| Dosing schedule | Once weekly | Once weekly |
| Doses available | 0.75, 1.5, 3.0, 4.5 mg | 0.25, 0.5, 1.0, 2.0 mg |
| Injection format | Single-use pen, fixed dose | Multi-dose pen, dial dose |
| Needle | Hidden auto-injector | Visible, standard pen |
| A1C reduction | ~1.0–1.5% | ~1.5–1.8% |
| Weight loss | ~2–4 kg | ~4–6 kg |
| CV outcomes trial | REWIND | SUSTAIN-6 |
| CV benefit shown | Yes — reduced MACE | Yes — reduced MACE |
| List price (US) | ~$987/month | ~$998/month |
Active Ingredients in Detail
Dulaglutide (Trulicity): A fusion of two modified GLP-1 peptides linked to an antibody fragment, giving it a long half-life of about 5 days. The antibody scaffolding helps prevent rapid breakdown by the enzyme DPP-4. It is delivered as a single fixed dose per pen.
Semaglutide (Ozempic): A modified GLP-1 analog with a fatty-acid side chain that binds to albumin, prolonging its action to about 7 days. The smaller, more streamlined molecule allows higher tissue penetration and stronger receptor activation. Semaglutide also comes as oral tablets (Rybelsus) and in higher-dose injectable form for weight loss (Wegovy).
Head-to-Head Trial: SUSTAIN-7
SUSTAIN-7 directly compared Ozempic and Trulicity in adults with type 2 diabetes. After 40 weeks:
- A1C reduction was 1.5 percent with semaglutide 0.5 mg vs 1.1 percent with dulaglutide 0.75 mg
- A1C reduction was 1.8 percent with semaglutide 1.0 mg vs 1.4 percent with dulaglutide 1.5 mg
- Weight loss was 4.6 kg with semaglutide 0.5 mg vs 2.3 kg with dulaglutide 0.75 mg
- Weight loss was 6.5 kg with semaglutide 1.0 mg vs 3.0 kg with dulaglutide 1.5 mg
- Rates of nausea and other GI side effects were similar
The trial established Ozempic as more potent at comparable doses, although both produced clinically meaningful improvements.
Cardiovascular Outcomes
Both drugs have shown reduced major adverse cardiovascular events (MACE) in dedicated trials:
- REWIND (Trulicity): 9,901 adults followed for 5.4 years; 12 percent reduction in MACE, including in patients without prior cardiovascular disease
- SUSTAIN-6 (Ozempic): 3,297 adults with T2D and high CV risk followed for 2.1 years; 26 percent reduction in MACE
The American Diabetes Association recommends GLP-1 receptor agonists with proven CV benefit for adults with established atherosclerotic cardiovascular disease or high cardiovascular risk regardless of A1C goal.
Side Effects and Tolerability
| Side Effect | Trulicity Frequency | Ozempic Frequency |
|---|---|---|
| Nausea | ~21% | ~20% |
| Diarrhea | ~13% | ~9% |
| Vomiting | ~12% | ~9% |
| Abdominal pain | ~9% | ~7% |
| Decreased appetite | ~9% | ~10% |
| Constipation | ~3% | ~5% |
| Injection site reaction | ~0.5% | ~0.2% |
Most GI side effects appear during the first 4 to 8 weeks of treatment and improve over time. Eating smaller, lower-fat meals helps reduce nausea.
Boxed Warnings
Both medications carry a boxed warning for thyroid C-cell tumors based on rodent studies. Human relevance remains unclear, but both are contraindicated in:
- Personal history of medullary thyroid carcinoma (MTC)
- Family history of MTC
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
Other shared cautions include pancreatitis, gallbladder disease, kidney injury from dehydration, hypoglycemia when combined with insulin or sulfonylureas, and possible mood changes.
Dosing and Convenience
Trulicity:
- Pre-filled single-use auto-injector
- Hidden needle — favored by needle-averse patients
- No dialing required — push button and inject
- Standard doses: 0.75 mg, 1.5 mg, 3 mg, 4.5 mg
- Escalation: 4 weeks per dose level
Ozempic:
- Multi-dose pen with rotating dose dial
- Visible needle attached separately
- Standard doses: 0.25 (starter), 0.5, 1.0, 2.0 mg
- Escalation: 4 weeks per dose level
- Newer Wegovy formulation goes up to 2.4 mg for weight loss
For comparing additional GLP-1 agents, see our broader Trulicity alternative guide.
Cost and Coverage
- List prices are nearly identical — about $990 to $1,000 per month
- Most US commercial insurance covers one or the other depending on formulary
- Both manufacturers offer savings cards that may reduce cost for eligible commercially insured patients
- Medicare Part D coverage varies significantly by plan
- Cash-pay through patient assistance programs may be available based on income
- Off-label or off-formulary use typically requires prior authorization
How Clinicians Choose Between Them
- Insurance formulary often dictates the choice — many plans prefer one over the other
- A1C goal — Ozempic for more aggressive lowering
- Weight-loss priority — Ozempic typically produces more weight loss
- Injection preference — Trulicity for needle-averse, single-step injection
- Cardiovascular risk profile — both are good options with proven CV benefit
- Tolerability history — switching to the other if one was poorly tolerated
- Cost considerations — savings cards, formulary placement
Switching Between the Two
Switching is reasonable when:
- Glucose control on current drug is inadequate at maximum tolerated dose
- Side effects are persistent or intolerable
- Insurance changes coverage
- Patient prefers a different injection format
Typical switch protocol: replace next scheduled weekly dose with starting dose of the alternative. Re-escalate as needed. Expect a temporary return of GI side effects during escalation. Do not overlap doses or take both drugs in the same week. Coordinate with your prescribing clinician.
Other Related Considerations
- Neither is approved for type 1 diabetes
- Trulicity is approved down to age 10 for T2D in adolescents; Ozempic is adult-only
- Neither is approved during pregnancy or breastfeeding
- Both require renal function check before initiation — dose adjustments may be needed in severe kidney impairment
- Long-term safety data exceeds 10 years for both
- See also our coverage of Trulicity generic name and whether Trulicity is a semaglutide
What People Often Confuse
| Confusion | Clarification |
|---|---|
| Trulicity and Ozempic are the same drug | Different molecules — dulaglutide vs semaglutide |
| Trulicity is generic Ozempic | No generic GLP-1 RA exists yet |
| Switching is automatic | Requires escalation and clinician supervision |
| One causes weight loss and the other does not | Both cause weight loss; Ozempic more so |
| Ozempic is the same as Wegovy | Same molecule, different doses and indications |
The Bottom Line
Trulicity and Ozempic are not the same drug. Both are once-weekly GLP-1 receptor agonist injections approved for type 2 diabetes, but Trulicity is dulaglutide and Ozempic is semaglutide. Ozempic tends to be more potent for A1C lowering and weight loss; Trulicity offers a hidden-needle, single-step auto-injector that some patients prefer. Both reduce cardiovascular events. Side-effect profiles are similar. The right choice depends on insurance, glycemic and weight-loss goals, injection preference, and tolerability. Discuss the trade-offs with your clinician before starting or switching. For broader treatment context, see our treatment hub and the American Diabetes Association medication overview.
